<SEC-DOCUMENT>0001372514-23-000070.txt : 20230509
<SEC-HEADER>0001372514-23-000070.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509070248
ACCESSION NUMBER:		0001372514-23-000070
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		23899900

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kprx-20230509.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:28a27ccc-2e81-4985-b4cb-0ba6b358b1d2,g:d71c4edf-0460-4ffd-b3fb-727ca26849fc,d:07a997167ea54500a7f1b55e7d3c3fe3--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20230509</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM180L2ZyYWc6ZTU2YjZhZGFiMWNmNDUzODlkNDM5ZGQyNzIwY2ZhY2MvdGFibGU6MzBmNTVmZGM5NTNlNGE0M2I5YWNhYWYzODYzOWQ1ODgvdGFibGVyYW5nZTozMGY1NWZkYzk1M2U0YTQzYjlhY2FhZjM4NjM5ZDU4OF8yLTEtMS0xLTM0NTg1_f60007a1-ae6c-4dbc-906a-d669dd7ee561">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM180L2ZyYWc6ZTU2YjZhZGFiMWNmNDUzODlkNDM5ZGQyNzIwY2ZhY2MvdGFibGU6MzBmNTVmZGM5NTNlNGE0M2I5YWNhYWYzODYzOWQ1ODgvdGFibGVyYW5nZTozMGY1NWZkYzk1M2U0YTQzYjlhY2FhZjM4NjM5ZDU4OF8zLTEtMS0xLTM0NTg1_a1127a24-0c22-4aed-8134-cb21d14f5753">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20230509.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-09</xbrli:startDate><xbrli:endDate>2023-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i07a997167ea54500a7f1b55e7d3c3fe3_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzAx_cdba8aa5-0767-4f2f-95d6-29e90a42d626">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18yMjM_d33fc90d-15e0-4321-90ff-79e923732312">May 9, 2023</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzEw_42d19a48-8199-4d68-b3b0-d0bd19d701c3">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzA2_d4eee289-52ce-4c36-894b-37a10a7ed3cd">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6OTcwNWRhNjM0YmM2NGYxZTkwNmMzYTRkNjc1ZDljNDUvdGFibGVyYW5nZTo5NzA1ZGE2MzRiYzY0ZjFlOTA2YzNhNGQ2NzVkOWM0NV8wLTAtMS0xLTM0NTg1_25b125dd-2698-40ba-b838-ba525b4089c5">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6OTcwNWRhNjM0YmM2NGYxZTkwNmMzYTRkNjc1ZDljNDUvdGFibGVyYW5nZTo5NzA1ZGE2MzRiYzY0ZjFlOTA2YzNhNGQ2NzVkOWM0NV8wLTEtMS0xLTM0NTg1_dd55a506-15d6-4553-ad98-cc767ac0f061">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzAz_e2acd393-c4cb-42be-881a-d2d92cda1017">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzE0_56c0c41b-1ba0-4d76-88d0-8ea8a7947bc6">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzEy_76e37bab-f383-4499-94bf-876b1976e681">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzE1_e85e303b-e123-465d-9b11-fab6e353ce05">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY180MTQ_5b002758-93f9-4c2d-970e-bd04dca08b7a">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY180MTg_48aaa088-2371-4f70-82a1-71fcda4146ca">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzA0_c35ce615-de84-4ed9-b28f-63d1317cdea7">224-9600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6ZGY5YzdmOTYwZTU1NGVjYzljYzYwODcxNGZlODc2NDkvdGFibGVyYW5nZTpkZjljN2Y5NjBlNTU0ZWNjOWNjNjA4NzE0ZmU4NzY0OV8wLTAtMS0xLTM0NTg1_700b03f5-9eb4-4eda-a8b4-79f219d27771">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6ZGY5YzdmOTYwZTU1NGVjYzljYzYwODcxNGZlODc2NDkvdGFibGVyYW5nZTpkZjljN2Y5NjBlNTU0ZWNjOWNjNjA4NzE0ZmU4NzY0OV8yLTAtMS0xLTM0NTg1_a66176cb-deac-45ae-9f9d-1459ec1322be">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6ZGY5YzdmOTYwZTU1NGVjYzljYzYwODcxNGZlODc2NDkvdGFibGVyYW5nZTpkZjljN2Y5NjBlNTU0ZWNjOWNjNjA4NzE0ZmU4NzY0OV80LTAtMS0xLTM0NTg1_851a752e-22ab-498e-8a60-a5a7e007d3fa">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6ZGY5YzdmOTYwZTU1NGVjYzljYzYwODcxNGZlODc2NDkvdGFibGVyYW5nZTpkZjljN2Y5NjBlNTU0ZWNjOWNjNjA4NzE0ZmU4NzY0OV82LTAtMS0xLTM0NTg1_a7373f14-e18f-4365-9b63-de521ae6f725">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6MDliODYzN2YyNTg3NDRlYmIwYjZiNGQ1OTU4OGJmMjUvdGFibGVyYW5nZTowOWI4NjM3ZjI1ODc0NGViYjBiNmI0ZDU5NTg4YmYyNV8xLTAtMS0xLTM0NTg1_104bde8f-88ce-4bb9-9bd5-0e333ba9630f">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6MDliODYzN2YyNTg3NDRlYmIwYjZiNGQ1OTU4OGJmMjUvdGFibGVyYW5nZTowOWI4NjM3ZjI1ODc0NGViYjBiNmI0ZDU5NTg4YmYyNV8xLTItMS0xLTM0NTg1_8c8dc37d-39cc-4e36-b641-0a9a3bb3f440">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6MDliODYzN2YyNTg3NDRlYmIwYjZiNGQ1OTU4OGJmMjUvdGFibGVyYW5nZTowOWI4NjM3ZjI1ODc0NGViYjBiNmI0ZDU5NTg4YmYyNV8xLTQtMS0xLTM0NTg1_3588873c-f4a0-48f8-a103-91261db04b34">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzA5_547fc5d8-d5c4-4652-9801-55b80e57d4d6">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07a997167ea54500a7f1b55e7d3c3fe3_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.02.&#160;&#160;&#160;&#160;Results of Operations and Financial Conditions.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 9, 2023, Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing financial results for the first quarter ended March 31, 2023 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i07a997167ea54500a7f1b55e7d3c3fe3_10"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.74pt"> Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-pressreleasemarch312.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991-pressreleasemarch312.htm">Press Release of Kiora Pharmaceuticals, Inc., dated as of May 9, 2023</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07a997167ea54500a7f1b55e7d3c3fe3_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.841%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President of Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 9, 2023</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-pressreleasemarch312.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if623c63b8a374f3c9591285093bd03a6_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Kiora Pharmaceuticals Reports First Quarter Results&#59; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Encinitas, CA -- May 9, 2023 -- Kiora Pharmaceuticals (NASDAQ&#58; KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA). </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CEO Commentary</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;This has been a pivotal quarter for our business resulting in several recently reported clinical development milestones,&#8221; said Brian M. Strem, Ph.D., president and CEO of Kiora. &#8220;Last month we reported preliminary results from our open-label study of KIO-301, our flagship asset, demonstrating profound improvements in light perception in a blind patient with RP. Importantly, the patient reported functional improvements consistent with objective functional MRI imaging results, showing elevated activity in regions of the brain activated by vision. Predictably, this activity diminished over time, consistent with our preclinical models, where the effect increases after dosing, continues to peak, and returns to baseline as the drug is eliminated. We are extremely encouraged by the early results from the low dose of 7.5&#181;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Additionally, we have fully enrolled the study and look forward to completing dosing in the higher dose groups of 25&#181;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and 50&#181;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  and reporting topline results on the full study by the end of this year.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Continuing the progress, we reported favorable and statistically significant outcomes from our Phase 2 clinical trial of KIO-201, evaluating its ability to accelerate wound healing after four weeks of therapy in patients with chronic, non-healing wounds on the ocular surface. If left untreated, these wounds can lead to infection, scarring, and vision loss. Notably, five out of eight patients achieved the primary endpoint at four weeks. The adverse event profile was also favorable to the advancement of this therapeutic candidate. </font><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These results, consistent with the five previous clinical trials evaluating KIO-201 in other corneal wounds, lay the foundation for planning and initiating a registration study in the U.S.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Lastly, in mid-April we </font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">enrolled the first patient in our Phase 2 trial of KIO-101. This indication focuses on a narrowly defined population of patients who suffer from ocular surface disease attributed to an underlying autoimmune condition. Current standard of care for these patients typically has little to no effect. With KIO-101, we believe by addressing the underlying condition locally with an eyedrop, we can help the millions of patients who suffer from the pain and discomfort associated with this condition.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;We continue to execute on our plan and achieve milestones on or ahead of schedule. The remainder of 2023 will build on our success as we plan to continue enrollment in the Phase 2 trial for KIO-101 in OPRA, begin planning a registration study of KIO-201, and expect to report topline results from the ABACUS trial in patients with RP.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Achieved and Upcoming Milestones&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The clinical development milestones that Kiora has achieved year to date include the following&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">KIO-301&#58; Reported initial results from ABACUS at ARVO in Q2 2023 </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">KIO-201&#58; Reported initial results from Phase 2 PCED study at ARVO in Q2 2023</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">KIO-101&#58; Initiated enrollment in Phase 2 trial for KIO-101 in Q2 2023</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company anticipates achieving the following clinical milestones&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">KIO-301&#58; Complete dosing all patients in ABACUS by end of Q3 2023</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">KIO-301&#58; Report topline results of the ABACUS study by year-end 2023</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">KIO-201&#58; Receive Orphan Drug Designation PCED in 2023</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">KIO-201&#58; Design and potentially initiate registration study following FDA guidance</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Results</font></div><div><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2023, research and development expenses were $0.4 million compared to $0.7 million last year. The decrease was primarily due to an increase of $0.3 million for credits expected from Australian and Austrian government programs related to research and development activities. General and administrative expenses for the first quarter were $1.3 million, compared to $1.7 million in the same period last year. The reduction is attributable to reduced consulting fees, lower facilities costs due to the consolidation of offices, and lower personnel costs due to staffing optimization and benefit cost savings.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net loss was $1.9 million for the first quarter of 2023 compared to $3.6 million for the first quarter of 2022. This decrease was primarily due to executive severance of $1.0 million that was incurred in the first quarter of 2022 and the reduction of general and administrative expenses as summarized.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Kiora ended the quarter with $3.4 million in cash and cash equivalents </font><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as well as $1.7 million in tax receivables related to Austrian and Australian research and development tax credit incentive programs. </font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, Kiora can draw on a $10 million equity line of credit (subject to certain limitations), of which there is approximately $9.6 million available.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">About Kiora Pharmaceuticals</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and&#47;or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis (OPRA). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a chemically cross-linked form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.</font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to news releases and SEC filings, we expect to post information on our website, </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">www.kiorapharma.com</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and&#47;or subscribe to email alerts.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Forward-Looking Statements</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of the statements in this press release are &#34;forward-looking&#34; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These &#34;forward-looking&#34; statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the potential ability of KIO-301 to restore vision in patients with RP, the expecting timing of the ABACUS study, Kiora&#8217;s ability to draw on its equity line of credit, the potential of KIO-201 to receive an orphan indication, and Kiora's ability to achieve the specific milestones described herein. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, the ability to obtain any required regulatory approvals, market and other conditions and certain risk factors described under the heading &#34;Risk Factors&#34; contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 23, 2023, or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Investor Contact</font></div><div style="margin-top:3pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Francina Agosti, Ph.D.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(617) 546-0742</font></div><div><font style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">francina&#64;reportablenews.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>kprx-20230509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:28a27ccc-2e81-4985-b4cb-0ba6b358b1d2,g:d71c4edf-0460-4ffd-b3fb-727ca26849fc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20230509" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20230509">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20230509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20230509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>kprx-20230509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:28a27ccc-2e81-4985-b4cb-0ba6b358b1d2,g:d71c4edf-0460-4ffd-b3fb-727ca26849fc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_c8efe8b7-1582-488a-b8ea-ff4a97927a8d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ce37976e-43ca-4b0a-a132-9e1aca394633_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_315dc46b-6eab-49d2-ae48-3a941bf608a7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3f2a6157-f11d-4430-bb48-1e39232d5dea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_31c671e4-a707-4cf0-9c24-5beb7cad266f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_768694ac-b145-4a5a-a099-cce4bec71574_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b0a20e0c-7e62-41e3-806c-4b6e64a57866_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_de1f5d6d-0c57-4789-999a-3879001bdf70_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3601de45-0603-4fb4-815d-0d15eecef013_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3886463e-bb29-47e2-b43b-5f442b0ef265_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3a38a95d-1dc3-4862-942c-17f16815fe4b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5fbd3199-73c7-4a7b-885e-bd9f3e609e92_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c2491726-1125-4ba8-af06-f2661b029c64_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f907e415-6a8d-404b-94c9-bf399caa241c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_77044c88-b6a9-4e49-858c-ebc8c467b0a8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_23e6d47f-4136-4fdb-812b-a4af6cffc5e2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_422fdc9f-f872-4f7c-97dc-dd347eec2d0f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2324a3ac-5800-45a8-9f7e-c5745f5a5fd6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_749f570c-70cd-43f1-bc88-4d02d4e11fed_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d27ddb13-b0c4-4dbd-8950-4870a45be1f5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_99746cf0-0198-4038-b286-530a02121c23_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_31927353-9513-402d-ab73-70353b890aa5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_16c028d6-e2e4-4df5-bc7d-559edcfb32d4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>kprx-20230509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:28a27ccc-2e81-4985-b4cb-0ba6b358b1d2,g:d71c4edf-0460-4ffd-b3fb-727ca26849fc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20230509.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f8268842-c5dd-4a0e-a815-e474d786f523" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_DocumentType_f8268842-c5dd-4a0e-a815-e474d786f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c9262327-7844-4152-baf4-f735262f58a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_DocumentPeriodEndDate_c9262327-7844-4152-baf4-f735262f58a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_20dd0c86-b430-4c88-a0a7-1a4f17c136cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityRegistrantName_20dd0c86-b430-4c88-a0a7-1a4f17c136cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4cacb567-0991-4425-b6e8-92afb6ff3bab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4cacb567-0991-4425-b6e8-92afb6ff3bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4a941075-4dff-430a-8ff9-b338e40b5323" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityTaxIdentificationNumber_4a941075-4dff-430a-8ff9-b338e40b5323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_55cf9f08-239b-4eed-a00d-3d1e5f50f941" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityFileNumber_55cf9f08-239b-4eed-a00d-3d1e5f50f941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3369cdb2-8571-4c34-a13a-0cfc1577fec1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityAddressAddressLine1_3369cdb2-8571-4c34-a13a-0cfc1577fec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_2c3c7a36-3a74-45a5-9f56-4df3be494503" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityAddressAddressLine2_2c3c7a36-3a74-45a5-9f56-4df3be494503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0d9969f6-7818-4265-85e4-1331c49895e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityAddressCityOrTown_0d9969f6-7818-4265-85e4-1331c49895e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_47fe4b96-7de3-43e3-8051-db1c29085422" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityAddressStateOrProvince_47fe4b96-7de3-43e3-8051-db1c29085422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a03260a8-3e96-4fd9-855b-9208177e6578" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityAddressPostalZipCode_a03260a8-3e96-4fd9-855b-9208177e6578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7a0915a8-f2c3-4d7a-a194-8f7e4a6ad765" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_CityAreaCode_7a0915a8-f2c3-4d7a-a194-8f7e4a6ad765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a16b7a27-5d07-4357-aaff-871e5d37e329" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_LocalPhoneNumber_a16b7a27-5d07-4357-aaff-871e5d37e329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e5b67d29-f2ee-45d4-a7da-7e19dd247a9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_WrittenCommunications_e5b67d29-f2ee-45d4-a7da-7e19dd247a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7385c792-3c90-450a-a77a-81db843c878a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_SolicitingMaterial_7385c792-3c90-450a-a77a-81db843c878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a18a6485-c7a2-49f0-b824-6fca27fb7e7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_PreCommencementTenderOffer_a18a6485-c7a2-49f0-b824-6fca27fb7e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ce06acd8-3f0f-4ad4-8531-ad4ba9fac9cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ce06acd8-3f0f-4ad4-8531-ad4ba9fac9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_61fa5eae-9aba-4451-b92d-a33bf7426406" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_Security12bTitle_61fa5eae-9aba-4451-b92d-a33bf7426406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d1454e74-daa9-4f9f-8cd6-58065c4c09bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_TradingSymbol_d1454e74-daa9-4f9f-8cd6-58065c4c09bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_07a5ba8c-5950-46ef-a15c-a5e2d8ff68c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_SecurityExchangeName_07a5ba8c-5950-46ef-a15c-a5e2d8ff68c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0138d02a-dc5a-4420-8ed0-85393298e3a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityEmergingGrowthCompany_0138d02a-dc5a-4420-8ed0-85393298e3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_040498a4-9bc3-46d6-8b1b-58c06d8ce5c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_EntityCentralIndexKey_040498a4-9bc3-46d6-8b1b-58c06d8ce5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f789f8e4-f623-48e5-958d-35a5f9d060fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeaa06c0-8712-4f82-8525-95f06ed388b4" xlink:to="loc_dei_AmendmentFlag_f789f8e4-f623-48e5-958d-35a5f9d060fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139933321762528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">332 Encinitas Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">224-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>kprx-20230509_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20230509.xsd" xlink:type="simple"/>
    <context id="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM180L2ZyYWc6ZTU2YjZhZGFiMWNmNDUzODlkNDM5ZGQyNzIwY2ZhY2MvdGFibGU6MzBmNTVmZGM5NTNlNGE0M2I5YWNhYWYzODYzOWQ1ODgvdGFibGVyYW5nZTozMGY1NWZkYzk1M2U0YTQzYjlhY2FhZjM4NjM5ZDU4OF8yLTEtMS0xLTM0NTg1_f60007a1-ae6c-4dbc-906a-d669dd7ee561">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM180L2ZyYWc6ZTU2YjZhZGFiMWNmNDUzODlkNDM5ZGQyNzIwY2ZhY2MvdGFibGU6MzBmNTVmZGM5NTNlNGE0M2I5YWNhYWYzODYzOWQ1ODgvdGFibGVyYW5nZTozMGY1NWZkYzk1M2U0YTQzYjlhY2FhZjM4NjM5ZDU4OF8zLTEtMS0xLTM0NTg1_a1127a24-0c22-4aed-8134-cb21d14f5753">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzAx_cdba8aa5-0767-4f2f-95d6-29e90a42d626">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18yMjM_d33fc90d-15e0-4321-90ff-79e923732312">2023-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzEw_42d19a48-8199-4d68-b3b0-d0bd19d701c3">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzA2_d4eee289-52ce-4c36-894b-37a10a7ed3cd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6OTcwNWRhNjM0YmM2NGYxZTkwNmMzYTRkNjc1ZDljNDUvdGFibGVyYW5nZTo5NzA1ZGE2MzRiYzY0ZjFlOTA2YzNhNGQ2NzVkOWM0NV8wLTAtMS0xLTM0NTg1_25b125dd-2698-40ba-b838-ba525b4089c5">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6OTcwNWRhNjM0YmM2NGYxZTkwNmMzYTRkNjc1ZDljNDUvdGFibGVyYW5nZTo5NzA1ZGE2MzRiYzY0ZjFlOTA2YzNhNGQ2NzVkOWM0NV8wLTEtMS0xLTM0NTg1_dd55a506-15d6-4553-ad98-cc767ac0f061">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzAz_e2acd393-c4cb-42be-881a-d2d92cda1017">332 Encinitas Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzE0_56c0c41b-1ba0-4d76-88d0-8ea8a7947bc6">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzEy_76e37bab-f383-4499-94bf-876b1976e681">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzE1_e85e303b-e123-465d-9b11-fab6e353ce05">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY180MTQ_5b002758-93f9-4c2d-970e-bd04dca08b7a">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY180MTg_48aaa088-2371-4f70-82a1-71fcda4146ca">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzA0_c35ce615-de84-4ed9-b28f-63d1317cdea7">224-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6ZGY5YzdmOTYwZTU1NGVjYzljYzYwODcxNGZlODc2NDkvdGFibGVyYW5nZTpkZjljN2Y5NjBlNTU0ZWNjOWNjNjA4NzE0ZmU4NzY0OV8wLTAtMS0xLTM0NTg1_700b03f5-9eb4-4eda-a8b4-79f219d27771">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6ZGY5YzdmOTYwZTU1NGVjYzljYzYwODcxNGZlODc2NDkvdGFibGVyYW5nZTpkZjljN2Y5NjBlNTU0ZWNjOWNjNjA4NzE0ZmU4NzY0OV8yLTAtMS0xLTM0NTg1_a66176cb-deac-45ae-9f9d-1459ec1322be">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6ZGY5YzdmOTYwZTU1NGVjYzljYzYwODcxNGZlODc2NDkvdGFibGVyYW5nZTpkZjljN2Y5NjBlNTU0ZWNjOWNjNjA4NzE0ZmU4NzY0OV80LTAtMS0xLTM0NTg1_851a752e-22ab-498e-8a60-a5a7e007d3fa">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6ZGY5YzdmOTYwZTU1NGVjYzljYzYwODcxNGZlODc2NDkvdGFibGVyYW5nZTpkZjljN2Y5NjBlNTU0ZWNjOWNjNjA4NzE0ZmU4NzY0OV82LTAtMS0xLTM0NTg1_a7373f14-e18f-4365-9b63-de521ae6f725">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6MDliODYzN2YyNTg3NDRlYmIwYjZiNGQ1OTU4OGJmMjUvdGFibGVyYW5nZTowOWI4NjM3ZjI1ODc0NGViYjBiNmI0ZDU5NTg4YmYyNV8xLTAtMS0xLTM0NTg1_104bde8f-88ce-4bb9-9bd5-0e333ba9630f">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6MDliODYzN2YyNTg3NDRlYmIwYjZiNGQ1OTU4OGJmMjUvdGFibGVyYW5nZTowOWI4NjM3ZjI1ODc0NGViYjBiNmI0ZDU5NTg4YmYyNV8xLTItMS0xLTM0NTg1_8c8dc37d-39cc-4e36-b641-0a9a3bb3f440">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGFibGU6MDliODYzN2YyNTg3NDRlYmIwYjZiNGQ1OTU4OGJmMjUvdGFibGVyYW5nZTowOWI4NjM3ZjI1ODc0NGViYjBiNmI0ZDU5NTg4YmYyNV8xLTQtMS0xLTM0NTg1_3588873c-f4a0-48f8-a103-91261db04b34">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3YTk5NzE2N2VhNTQ1MDBhN2YxYjU1ZTdkM2MzZmUzL3NlYzowN2E5OTcxNjdlYTU0NTAwYTdmMWI1NWU3ZDNjM2ZlM18xL2ZyYWc6ZDhlNzc2ZWE2NGFlNDE1NDk0Y2M2ODEwYzFjYmM0ZmMvdGV4dHJlZ2lvbjpkOGU3NzZlYTY0YWU0MTU0OTRjYzY4MTBjMWNiYzRmY18xMzA5_547fc5d8-d5c4-4652-9801-55b80e57d4d6">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( %<XJ58'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 5SBI5M)D@QKO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 5SBI5IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !7
M.*E64:O^=5L$   9$0  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ 5SBI5I^@&_"Q @  X@P   T
M         ( !GPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !7.*E6EXJ[
M',     3 @  "P              @ %[#P  7W)E;',O+G)E;'-02P$"% ,4
M    " !7.*E6JL0B%C,!   B @  #P              @ %D$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ 5SBI5B0>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ 5SBI5F60>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kprx-20230509.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="kprx-20230509.htm">kprx-20230509.htm</File>
    <File>ex991-pressreleasemarch312.htm</File>
    <File>kprx-20230509.xsd</File>
    <File>kprx-20230509_lab.xml</File>
    <File>kprx-20230509_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "kprx-20230509.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "kprx-20230509.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20230509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20230509_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kprx-20230509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20230509",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20230509.htm",
      "contextRef": "i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.eyegatepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20230509.htm",
      "contextRef": "i98f6258889ae4ef2b070a68e5691ba43_D20230509-20230509",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001372514-23-000070-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-23-000070-xbrl.zip
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M>&5\8BJV#DL,'8$1( ASZ2 SV)DZ.QVHUP61REC08_-J1W1GR( U$HBL[I2
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M:K5]<VJ514X_?/!D]U":G2E%IU1R.<VZIQ?2F_+G1/@/F[SX%U!+ P04
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MJF'/52BGFJ^;NEK8]5F8B'O#6EJ<QK'P12P II(EZ",QL9QDF P#CS*,+*>
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M-$0>L")I _/R0H31*$M5 ;J>R>Z+J ( ,)K>;'O.J9&V:IHR6!RXM$QKE[W
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M 6-Y,0BV=DSAA;BR)3?B4_C32P?A[G\!4$L#!!0    ( %<XJ5;>*VFA;0(
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MNPT+ABNV^WZQADZPV^W%Z ]02P,$%     @ 5SBI5KX!0E6/"@  $6$  !4
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M;!E0F;=\[@OJ=+,C+R^$+'3]:@C!T/_>":$?_GSYGTXB$DVX#&(21Q+@@%.
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MVS85=&>MGUS@0)C[%IP=;'3?A+/I^.=LP]D1WLZ-.+OLW6><GWX']%?M>1)
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M;6%R8V@S,3(N:'1M4$L! A0#%     @ 5SBI5A.F]V2O%   EX4  !$
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8;6Q02P4&      4 !0!0 0  *CL

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
